Susan Richards

7.7k total citations · 2 hit papers
103 papers, 5.0k citations indexed

About

Susan Richards is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Susan Richards has authored 103 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 31 papers in Public Health, Environmental and Occupational Health and 28 papers in Immunology. Recurrent topics in Susan Richards's work include Acute Lymphoblastic Leukemia research (29 papers), Lysosomal Storage Disorders Research (23 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Susan Richards is often cited by papers focused on Acute Lymphoblastic Leukemia research (29 papers), Lysosomal Storage Disorders Research (23 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Susan Richards collaborates with scholars based in United States, United Kingdom and France. Susan Richards's co-authors include Anthony H. Goldstone, Jacob M. Rowe, Adele K. Fielding, Hillard M. Lazarus, Mark R. Litzow, David I. Marks, Selina M. Luger, Martin S. Tallman, Andrew McMillan and Georgina Buck and has published in prestigious journals such as The Lancet, Blood and Nature Biotechnology.

In The Last Decade

Susan Richards

100 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2006 591 citations Adele K. Fielding, Susan Richards et al. Blood profile →
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

2007 537 citations Anthony H. Goldstone, Susan Richards et al. Blood profile →

Peers

Countries citing papers authored by Susan Richards

Since Specialization

Citations

This map shows the geographic impact of Susan Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Richards more than expected).

Fields of papers citing papers by Susan Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Richards. The network helps show where Susan Richards may publish in the future.

Co-authorship network of co-authors of Susan Richards

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Richards. A scholar is included among the top collaborators of Susan Richards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Richards. Susan Richards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa 2025 ·The Journal of Pediatrics ·David Kronn, James Davison, Alexander Broomfield, Anaïs Brassier, François Labarthe, Si Houn Hahn, Satoko Kumada, Hirotaka Ohki, S. Grace Prakalapakorn, Catherine Wilson, Kristina An Haack, (unknown), Susan Richards, Susan Sparks, (unknown), Tianyue Zhou, Yin‐Hsiu Chien, Priya S. Kishnani	0
2	Reduction in kidney function decline and risk of severe clinical events in agalsidase beta–treated Fabry disease patients: a matched analysis from the Fabry Registry 2024 ·Clinical Kidney Journal ·Julie L. Batista, Ali Hariri, Manish Maski, Susan Richards, (unknown), (unknown), Elvira Ponce, Christoph Wanner, Robert J. Desnick	4
3	Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000‐L Scale in Participants with Pompe Disease: A Phase 3/4 Open‐Label Study 2023 ·Clinical Pharmacology in Drug Development ·(unknown), Fabrice Hurbin, Magali Periquet, Susan Richards, (unknown), (unknown), Kristina An Haack	4
4	A Novel and Sensitive LC/MS/MS Method for Quantitation of Pyochelin in Human Sputum Samples from Cystic Fibrosis Patients 2019 ·Allena Ji, (unknown), (unknown), (unknown), Lynn E. Taylor, Chung Lee, Susan Richards, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
5	Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency) 2015 ·Genetics in Medicine ·Margaret M. McGovern, Melissa Wasserstein, Brian Kirmse, W. Lane Duvall, Thomas D. Schiano, Beth L. Thurberg, Susan Richards, Gerald F. Cox	46
6	A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays 2015 ·Journal of Immunological Methods ·(unknown), Yuanxin Xu, (unknown), Valerie Theobald, Susan Richards	64
7	Levels of Teen Dating Violence and Substance Use in an Urban Emergency Department 2014 ·Journal of Developmental & Behavioral Pediatrics ·Michael J. Mason, Leah Campbell, Nikola Zaharakis, Robin L. Foster, Susan Richards	8
8	Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) 2013 ·Neurology ·Per Soelberg Sørensen, Douglas L. Arnold, Jeffrey A. Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Cary Twyman, Stephen Lake, David Margolin, Susan Richards, Crystal Sung, Michael Panzara, Alastair Compston	4
9	An Altered Immune Response, but Not Individual Cationic Antimicrobial Peptides, Is Associated with the Oral Attenuation of Ara4N-Deficient Salmonella enterica Serovar Typhimurium in Mice 2012 ·PLoS ONE ·Kristi L. Strandberg, Susan Richards, Rita Tamayo, (unknown), John S. Gunn	13
10	Cationic antimicrobial peptides serve as activation signals for the Salmonella Typhimurium PhoPQ and PmrAB regulons in vitro and in vivo 2012 ·Frontiers in Cellular and Infection Microbiology ·Susan Richards, Kristi L. Strandberg, (unknown), John S. Gunn	45
11	Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry 2011 ·Molecular Genetics and Metabolism ·William R. Wilcox, Gabor E. Linthorst, Dominique P. Germain, Ulla Feldt‐Rasmussen, Stephen Waldek, Susan Richards, Dana Beitner‐Johnson, Marta Cizmarik, J. Alexander Cole, (unknown), David G. Warnock	57
12	Atypical immunologic response in a patient with CRIM-negative Pompe disease 2011 ·Molecular Genetics and Metabolism ·Mary‐Alice Abbott, Sean N. Prater, Suhrad G. Banugaria, Susan Richards, Sarah P. Young, Amy S. Rosenberg, Priya S. Kishnani	24
13	Murine Antithymocyte Globulin T-Cell Depletion Is Mediated Predominantly by Macrophages, but the Fas/FasL Pathway Selectively Targets Regulatory T Cells 2011 ·Transplantation ·(unknown), Susan Richards, John M. Williams, Richard D. Garman, Melanie C. Ruzek	14
14	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) breakdown → 2007 ·Blood ·Anthony H. Goldstone, Susan Richards, Hillard M. Lazarus, Martin S. Tallman, Georgina Buck, Adele K. Fielding, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Letizia Foroni, Elisabeth Paietta, Mark R. Litzow, David I. Marks, Jill Durrant, Andrew McMillan, Ian M. Franklin, Selina M. Luger, Niculae Ciobanu, Jacob M. Rowe	537
15	Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics 2007 ·Journal of Immunological Methods ·Shalini Gupta, Stephen R. Indelicato, (unknown), Thomas T. Kawabata, Marian Kelley, Anthony R. Mire‐Sluis, Susan Richards, Bonita Rup, Elizabeth W. Shores, Steven J. Swanson, Eric Wakshull	161
16	Recognition and Integration of Multiple Environmental Signals by the Bacterial Sensor Kinase PhoQ 2007 ·Cell Host & Microbe ·John S. Gunn, Susan Richards	13
17	Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI 2002 ·British Journal of Haematology ·Judith M. Chessells, G Harrison, Susan Richards, Brenda Gibson, Clifford C. Bailey, Frank G. H. Hill, Ian Hann	18
18	Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity 2001 ·American Journal of Hematology ·Elisabeth Paietta, Donna Neuberg, Susan Richards, (unknown), (unknown), Janis Racevskis, Gordon W. Dewald, Jacob M. Rowe, P H Wiernik, (unknown)	26
19	Severe cytopenias associated with the sequential use of busulphan and interferon‐alpha in chronic myeloid leukaemia 1994 ·British Journal of Haematology ·Patricia Shepherd, Susan Richards, N. C. Allan	11
20	Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: a long‐term follow‐up 1989 ·British Journal of Haematology ·Lorna M. Secker‐Walker, Judith M. Chessells, (unknown), G. John Swansbury, Susan Richards, Sylvia D. Lawler	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact